Treatment of knee meniscus with platelet lysis

Phase 2

Recruiting

• Conditions: Knee meniscus.; Cystic meniscus, unspecified medial meniscus, unspecified knee; M23.005

• Registration Number: IRCT20160422027520N18
• Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 September 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

Men and women between the ages of 18 and 75 with OA diagnosis based on the American College of Rheumatology
Analog scale of knee pain (VAS) equal to or greater than 2.5
People with at least 6 months of history of meniscus in both knees
Radiological classification scale Kellgren-Lawrence 1 or 2
The availability of individual during the study period
BMI Between 20 and 35
Positive joint line tenderness test
Positive thessaly test

Exclusion Criteria

Pregnant women or women who are breastfeeding
People with malignancy,People with severe heart disease, uncontrolled diabetes mellitus, rheumatoid arthritis, hemorrhagic diseases, history of anemia, arthritis, fibromyalgia and chronic fatigue syndrome
Those linked to acetaminophen or Vicodin or a history of drug misuse
History of cortisone injections in the last 6 weeks
The use of non-steroidal anti-inflammatory drugs 1 week ago
Having hemoglobin less than 11 g / dl and platelet count less than 150000 / mµ
The use of inhibitors of platelet aggregation and anti-coagulation such as heparin
History of knee surgery in the last 3 months
Extraordinary deformation (varus >5?, valgus >5?)

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Determining knee pain by VAS in all phases of clinical trial. Timepoint: 1, 3, 6 and 12 months after the first injection. Method of measurement: Questionnaire (VAS).;Determination of knee function by WOMAC and KOOS in all phases of clinical trial. Timepoint: 1, 3, 6 and 12 months after the first injection. Method of measurement: Questionnaire (WOMAC), Questionnaire (KOOS).;Determine the range of knee motion by manual joiniometry in all phases of clinical trial. Timepoint: 1, 3, 6 and 12 months after the first injection. Method of measurement: Range of motion (Degree).